GATC Health Senior Leadership Presents at Two Key Industry Forums Focused on AI, Capital Efficiency, and Addiction Innovation

GATC Health Senior Leadership Presents at Two Key Industry Forums Focused on AI, Capital Efficiency, and Addiction Innovation

Recent participation at Biocom Converge and NDASA reinforced GATC’s differentiated position at the intersection of predictive AI, biotech finance, and human-impact therapeutic development

Irvine, CA — April 30, 2026 — GATC Health is pleased to share recent visibility across two distinct but strategically aligned industry gatherings in late April: Biocom’s Converge Summit in South San Francisco and the NDASA 2026 Conference and Trade Show in Orange County. Taken together, these appearances gave GATC the opportunity to engage with biotech executives, investors, AI stakeholders, and addiction-policy leaders.  

At Biocom’s Converge Summit, an executive-level conference focused on collaboration across life science and technology in California, GATC Chief Business Officer Tyrone Lam participated in the panel “De-risking Economic Hurdles: Getting Drugs Into the Pipeline” on Thursday, April 23, at The Forum in South San Francisco. 

The clear take away at this event is that biotech investors and executives are requiring better predictive tools to make better capital decisions. Capital appears to be consolidating into a smaller set of companies while generative AI is creating a much larger wave of new molecules and programs competing for attention and funding.

Biocom also reinforced another theme that aligns closely with GATC’s strengths: that drug discovery is undergoing a fundamental transformation from a serendipity-driven, trial-and-error scientific endeavor into a more predictive, rational, and increasingly automated molecular engineering discipline. That evolution is being driven by AI, systems biology, and advanced automation — all of which support GATC’s positioning that the future of biopharma will depend not only on making more molecules, but on understanding earlier which molecules, programs, and development decisions have the highest probability of success. Within Ty’s panel discussion, this distinction resonated clearly. While many AI conversations remain centered on discovery and trial optimization, GATC emphasized that one of the most practical and near-term uses of AI is to improve scientific and capital decisions before resources are committed, producing faster and more measurable ROI for the entire ecosystem.

On April 28th, GATC also appeared at the 2026 NDASA Conference and Trade Show in Orange County. As the industry’s premier annual event, NDASA brings together top experts and professionals dedicated to the mission of maintaining safe, drug-free workplaces. 

This year’s keynote address was delivered by Dr. Stephen Loyd, Director of Drug Policy for West Virginia, who invited GATC Health’s Chief Business Officer, Tyrone Lam, to discuss the company’s efforts in combating Opioid Use Disorder. Lam highlighted the promise of GATC-1021, a drug candidate discovered via Operon ™, our proprietary AI platform, which demonstrated the technology’s ability to identify novel targets and compounds.